RETEVMO Drug Patent Profile

When do Retevmo patents expire, and what generic alternatives are available?

Retevmo is a drug marketed by Eli Lilly And Co and is included in two NDAs. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and forty-seven patent family members in forty-one countries.

The generic ingredient in RETEVMO is selpercatinib. One supplier is listed for this compound. Additional details are available on the selpercatinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Retevmo

Retevmo was eligible for patent challenges on May 8, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 10, 2038. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

Summary for RETEVMO

International Patents:	147
US Patents:	6
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	34
Clinical Trials:	5
Patent Applications:	4,960
Drug Prices:	Drug price information for RETEVMO
What excipients (inactive ingredients) are in RETEVMO?	RETEVMO excipients list
DailyMed Link:	RETEVMO at DailyMed

See drug prices for RETEVMO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for RETEVMO

Constraining patent/regulatory exclusivity:

10,112,942*PED

NDA:

213246

Dosage:

CAPSULE;ORAL

Constraining patent/regulatory exclusivity:

10,112,942*PED

NDA:

218160

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for RETEVMO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Massachusetts General Hospital	Phase 2
Eli Lilly and Company	Phase 2
Southwest Oncology Group	Phase 2

See all RETEVMO clinical trials

Pharmacology for RETEVMO

Drug Class	Kinase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Cytochrome P450 2C8 Inhibitors Cytochrome P450 3A Inhibitors Multidrug and Toxin Extrusion Transporter 1 Inhibitors P-Glycoprotein Inhibitors Rearranged during Transfection (RET) Inhibitors

Paragraph IV (Patent) Challenges for RETEVMO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RETEVMO	Capsules	selpercatinib	40 mg and 80 mg	213246	1	2024-05-08

US Patents and Regulatory Information for RETEVMO

RETEVMO is protected by six US patents and nineteen FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 10,112,942.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eli Lilly And Co	RETEVMO	selpercatinib	CAPSULE;ORAL	213246-002	May 8, 2020		RX	Yes	Yes
Eli Lilly And Co	RETEVMO	selpercatinib	CAPSULE;ORAL	213246-002	May 8, 2020		RX	Yes	Yes	10,137,124*PED				Y
Eli Lilly And Co	RETEVMO	selpercatinib	TABLET;ORAL	218160-004	Apr 10, 2024		RX	Yes	Yes

EU/EMA Drug Approvals for RETEVMO

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Eli Lilly Nederland B.V.	Retsevmo	selpercatinib	EMEA/H/C/005375Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC)advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitoradvanced RET fusion-positive thyroid cancer who require systematic therapy following prior treatment	Authorised	no	no	no	2021-02-11

International Patents for RETEVMO

When does loss-of-exclusivity occur for RETEVMO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

Hungary

Israel

Japan

Jordan

Lithuania

Malaysia

Mexico

Moldova, Republic of

Morocco

New Zealand

Peru

Philippines

Poland

Portugal

Saudi Arabia

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering RETEVMO around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	109919
Argentina	109920
Australia	2017342022

Retevmo (selpercatinib) Market Dynamics and Financial Trajectory: Exclusivity, Pricing, Uptake, Competition, and IP/Regulatory Risk

Last updated: July 13, 2026

Retevmo (selpercatinib) has scaled into one of the leading oncology launches in the precision-medicine era, driven by high response rates in RET-altered NSCLC and RET-mutant medullary thyroid cancer (MTC), plus expansion into earlier-stage and broader RET-driven indications. The revenue path is shaped less by near-term generic threats and more by (1) label expansion and sequencing (front-line use vs post-therapy), (2) payer acceptance and site-of-care economics, (3) competition from other RET inhibitors and next-generation targeted agents, and (4) patent and exclusivity durability around the evolving regimen landscape.

Retevmo (selpercatinib) financial trajectory: how revenues moved from launch through today

Answer: Public reporting and investor coverage track Retevmo’s progression from early cohort-driven uptake to meaningful multi-indication sales, with growth tied to continued label expansion (NSCLC, MTC) and durable penetration in RET-positive patient segments.

Key commercial drivers in the trajectory

• Indication pull-through: Retevmo’s adoption accelerates when clinicians can use it earlier in the treatment line for RET-altered disease or when treatment guidelines normalize RET testing and targeted prescribing.
• Testing and workflow: Sales growth is strongly correlated with the rate at which hospitals implement routine RET testing in lung cancer and thyroid workflows, because RET inhibitors are only used in biomarker-confirmed populations.
• Combination and sequencing dynamics: Even without formal combination claims, real-world sequencing affects share versus chemotherapy and competing targeted agents.
• Payer access and formulary placement: Durable uptake depends on prior authorization success, preferred-tier status in oncology formularies, and drug affordability programs where applicable.

Revenue inflection points typically observed for Retevmo

• Initial NSCLC ramp as confirmed RET-altered NSCLC patients begin targeted therapy.
• MTC expansion when RET-mutant MTC becomes a larger share of addressable demand and when access improves.
• Label and guideline adoption cycles that convert clinical trial endpoints into standard-of-care prescribing patterns.

What the financial trajectory implies for risk

Retevmo’s commercial trajectory is exposed to:

• Slower patient growth if RET testing uptake stalls.
• Share erosion if competing RET inhibitors offer superior tolerability, intracranial activity, or guideline alignment.
• Therapy line displacement if new data supports earlier use of competitor agents or if resistance patterns change post-first-line targeted therapy.

What market dynamics affect Retevmo (selpercatinib) adoption and pricing?

Answer: Adoption is primarily driven by RET biomarker testing penetration, payer access mechanics for high-cost oral oncology drugs, and the competitive landscape in RET inhibition.

Demand-side dynamics

• Biomarker testing penetration: Broader next-generation sequencing panels increase the denominator of RET-positive patients identified and treated.
• Line-of-therapy positioning: Retevmo’s realized sales depend on how payers and clinicians position it relative to chemoimmunotherapy and competing targeted options.
• Geographic heterogeneity: Uptake varies by coverage policy, oncology pathway governance, and testing infrastructure.

Payer and pricing dynamics

• Oral oncology reimbursement: Managed care utilization controls (prior auth, quantity limits in some settings, specialty pharmacy distribution) determine how fast new patient starts convert into net sales.
• Price and net-to-gross: Public pricing is not the whole story; discounts, rebates, and patient assistance programs determine realized margins and payer acceptance.
• Budget impact: Health technology assessments and payer committees react to both clinical value and budget predictability, especially when multiple targeted options coexist.

Competitive dynamics in RET oncology

Retevmo competes within a clustered class of RET-directed therapies. Market share can shift quickly when new entrants demonstrate improved efficacy in specific resistance subsets, better tolerability, or superior central nervous system outcomes.

How strong is the competitive landscape for Retevmo (selpercatinib) vs other RET inhibitors?

Answer: The competitive set includes other RET inhibitors and broader targeted oncology strategies. Retevmo’s differentiation has historically come from clinical efficacy and durability across RET-altered NSCLC and RET-mutant MTC, but share is at risk as rival agents gain traction through guideline integration and payer preferences.

Where Retevmo typically wins

• High objective response and clinically meaningful disease control in RET-altered NSCLC and MTC populations.
• Clinically manageable safety profile relative to chemotherapy in routine practice.
• Doctor comfort and established prescribing after label expansions.

Where share pressure can emerge

• Resistance-driven progression: Subsequent therapy options after selpercatinib resistance can shift.
• New data favoring competitors in front-line settings or resistant CNS disease.
• Payer switching to preferred agents when clinical endpoints appear comparable and formulary decisions tighten.

When does Retevmo exclusivity end, and what does that mean for generic entry risk?

Answer: Retevmo’s near-term commercial risk from standard generic entry is structurally limited by patent and exclusivity protection, with the larger threat coming from patent-specific Paragraph IV challenges and settlements rather than immediate market liberalization.

What determines generic entry timing

• Regulatory exclusivity: Includes FDA exclusivity frameworks tied to new chemical entities and new clinical investigations, which set a floor for first generic filings in many cases.
• Orange Book patent landscape: Each listed patent can independently constrain generic entry by blocking FDA approval until expiration or successful patent litigation resolution.
• Method and formulation patents: Even when the active ingredient is protected, additional patents can block specific dosing regimens, combinations, or manufacturing approaches.

Paragraph IV challenge mechanics

• If a generic applicant files a Paragraph IV certification and initiates litigation, a settlement can delay launch, while an adverse decision can accelerate entry.
• For branded oral oncology products, settlements often include time-bound payments, supply agreements, or “design-around” pathways that preserve partial exclusivity.

What patents protect Retevmo (selpercatinib), and how many are in the Orange Book?

Answer: Retevmo’s protection is typically enforced through an Orange Book family covering compound, polymorphs/solid state, formulations, and potentially methods of treatment for specific RET-altered disease contexts.

How to evaluate protection strength

A practical assessment uses three levers:

1. Count of Orange Book listings (more patents increase the probability at least one survives).
2. Expiration dates by patent type (compound vs formulation vs method-of-use).
3. Litigation history (filed challenges and court outcomes predict durability better than patent text alone).

This section depends on the current FDA Orange Book listing set and known litigation dockets for selpercatinib; without those live records, the patent-count and expiration-date specifics cannot be stated accurately.

What is the FDA status of Retevmo (selpercatinib), and how do pathways affect launch and lifecycle?

Answer: Retevmo is an FDA-approved targeted therapy for RET-driven cancers with ongoing lifecycle developments that can extend commercial duration through label expansions and supplemental approvals.

How FDA actions influence commercialization

• Label expansions widen the treatable population and increase addressable demand.
• Supplemental approvals can support additional dosing options, safety updates, or expanded biomarkers.
• Postmarketing requirements and confirmatory studies can shape clinicians’ confidence and payer coverage decisions.

How do patent litigation and settlements influence Retevmo’s commercial risk?

Answer: Litigation risk is not limited to generics. Court outcomes can also shape the ability of competitors to launch “authorized” alternatives or use design-around formulations that may be less constrained by the strongest patents.

Market effects of litigation

• Delayed or accelerated generic entry influences forecasted net sales.
• Settlement terms can cap downside by keeping market exclusivity intact beyond headline patent expirations.
• Uncertainty premium: Ongoing litigation can change how payers negotiate rebates and how providers plan formularies.

Specific litigation dates, parties, and docket outcomes are required for a correct case-driven analysis and are not provided here.

What formulations and dosing regimens of Retevmo are most likely to face IP barriers?

Answer: For oral targeted kinase inhibitors, the most litigated areas are commonly solid-state properties (polymorphs, hydrates), tablet or capsule formulation specs, and manufacturing process claims.

Formulation IP risk pathways

• Design-around risk: If a generic can use a different crystalline form or manufacturing process outside the claim scope, it may file with narrower certifications.
• Bioequivalence strategy: Even if the active ingredient is protected, specific release profiles or excipient systems can create barriers tied to formulation patents.

Claim-specific formulation coverage and expiration dates require Orange Book patent and claim text access.

What generic entry scenarios could threaten Retevmo sales, and how likely are they?

Answer: The primary realistic scenario is a staggered series of Paragraph IV challenges where different patents expire or are invalidated in sequence, leading to staged generic or authorized generic launches.

Entry scenarios

• Early entry if key method-of-use patents fall: If method-of-treatment coverage is narrowed or invalidated, generics can enter for certain indications.
• Delayed entry if compound claims hold: Compound protection often anchors the earliest barriers; if upheld, generic entry can be pushed out.
• Launch limited to specific indications or strengths: Even with approval, label carve-outs tied to remaining patents can reduce competitive intensity.

Retevmo regional market dynamics: how do geographic coverage and payer systems change outcomes?

Answer: Uptake differs by country due to variations in:

• reimbursement policy for oncology precision drugs,
• biomarker testing coverage and guideline adoption,
• contracting structures for high-cost oral therapies.

Where commercial performance is typically more resilient

• Systems with established precision oncology pathways and faster biomarker adoption tend to show faster Retevmo starts.
• Markets with stronger specialty pharmacy infrastructure maintain steadier adherence and refill dynamics for oral kinase inhibitors.

Key Takeaways

• Retevmo’s financial trajectory is driven primarily by RET biomarker testing penetration, label expansion, payer access, and line-of-therapy positioning against other RET inhibitors.
• The near-term generic threat is constrained by patent and exclusivity frameworks; the more actionable risk comes from Paragraph IV challenges and patent-specific outcomes that enable time-staggered entry.
• Competitive pressure is likely to increase as other RET inhibitors and broader targeted oncology strategies integrate into guidelines, particularly if they demonstrate advantages in resistance subsets or CNS activity.
• The next commercial inflection for Retevmo is tied to the pace of testing adoption, payer contracting behavior, and uptake across expanded indications rather than immediate generic displacements.

FAQs

1. How does RET testing penetration affect real-world Retevmo patient starts and net sales?
2. Which payer levers most influence Retevmo formulary access for RET-altered NSCLC and RET-mutant MTC?
3. What Paragraph IV challenge structures most commonly threaten long-duration branded oncology products like Retevmo?
4. How do guideline updates on RET-driven cancers change sequencing outcomes for selpercatinib versus competing RET inhibitors?
5. What indication-specific exclusivity or patent expirations would most likely reduce Retevmo revenue even if the drug remains protected elsewhere?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Orange Book).
2. FDA. Drug Approval Reports and labeling for Retevmo (selpercatinib). (FDA approvals and label).
3. FDA. Clinical Pharmacology and Biopharmaceutics Review documents for selpercatinib (Retevmo). (FDA review materials).

DrugChatter Q&A for RETEVMO

Eli lilly retevmo data protection expiry 2025?
Retevmo 40 mg capsule price?
Retevmo mechanism of action?
Retevmo capsule supplier in india?